Sudan Loganathan
Stock Analyst at Stephens & Co.
(0)
# 4627
Out of 5,240 analysts
24
Total ratings
30.00%
Success rate
-17.80%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Blueprint Medicines | Reiterates: Overweight | 140 140 | 105.91 | 32.19% | 2 | Jan 2, 2025 | |
Elevation Oncology | Reiterates: Overweight | 5 5 | 0.73 | 584.93% | 2 | Dec 6, 2024 | |
Actinium Pharma | Reiterates: Overweight | 5 5 | 1.27 | 293.7% | 2 | Nov 19, 2024 | |
Catalyst Pharmaceuti... | Initiates Coverage On: Overweight | 35 | 22.19 | 57.73% | 1 | Nov 18, 2024 | |
IDEAYA Biosciences | Initiates Coverage On: Overweight | 51 | 23.59 | 116.19% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 4 | 3.9 | 2.56% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 65 | 41.17 | 57.88% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 55 | 17.74 | 210.03% | 1 | Nov 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 25 | 14.59 | 71.35% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 6 | 1.72 | 248.84% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 9.54 | 214.47% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 13 | 1.41 | 821.99% | 1 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 29 | 36.33 | -20.18% | 2 | Oct 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 31 31 | 19.73 | 57.12% | 2 | Oct 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 25 | 12.99 | 92.46% | 2 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 5 | 0.47 | 963.83% | 2 | May 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 1.9 | 952.63% | 1 | May 14, 2024 |